Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 14Neoplasm Metastasis 7Recurrence 3Neoplasms 2Melanoma 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pre-menopausal Breast Cancer 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Meningioma 1Kidney Neoplasms 1Head and Neck Squamous Cell Cancer 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ductal, Breast 1Advanced or Metastatic ER+ Breast Cancer 1Advanced and Selected Solid Tumors 1Advanced Solid Tumors With an Alteration of the PIK3CA Gene 1Advanced Solid Tumor 1Acrocephalosyndactylia 13rd Line GIST 1

Interventions

NVP-BKM120 1Imatinib Mesylate 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × 3rd Line GIST × Alpelisib × Clear all
NCT01735968 2020-12-21

A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

Novartis

Phase 1 Completed
56 enrolled
Sarcoma

3rd Line GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡